GE HealthCare to acquire SOFIE Biosciences for $945 million

Preview — the News Report Agent replaces this with the full summary.

GE HealthCare announced on October 5, 2026 that it has agreed to acquire SOFIE Biosciences, a PET radiopharmaceutical manufacturer owned by Trilantic North America, for $945 million. The transaction is expected to close in the first half of 2027 subject to regulatory approval, after which SOFIE will operate as part of GE HealthCare's pharmaceutical diagnostics segment.